Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Share-based Compensation (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Share-based Compensation data on record, last reported at $11.4 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 57.83% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $43.2 million, up 30.43%, while the annual FY2025 figure was $43.2 million, 30.43% up from the prior year.
  • Share-based Compensation reached $11.4 million in Q4 2025 per OCUL's latest filing, down from $11.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $11.7 million in Q3 2025 and bottomed at $3.1 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $6.3 million, with a median of $4.5 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 155.9% in 2024, then dropped 14.3% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $3.8 million in 2021, then rose by 10.23% to $4.2 million in 2022, then increased by 2.22% to $4.3 million in 2023, then surged by 66.29% to $7.2 million in 2024, then surged by 57.83% to $11.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $11.4 million in Q4 2025, $11.7 million in Q3 2025, and $9.7 million in Q2 2025.